Clinical Trial Update: Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing LC15-0444 with sitagliptin added to ongoing metformin therapy in adults with type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LC15-0444
• Sitagliptin (sitagliptin)
• metformin (metformin)

Snippet

Sponsor: LG Life Sciences | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED